CarelogyReported
Carelogy is the developer of the 'CatsMe' AI app that detects pain in cats.
The round
Carelogy, the company behind the AI-powered cat pain detection app ‘CatsMe,’ has successfully secured JPY 70.0 million in a seed funding round. The investment was announced on February 10th. While a lead investor was not disclosed, the round saw participation from QXLV (Quantum Leap Ventures), Kepple Capital, Sawada Investment, and several individual investors. The valuation of Carelogy at this stage has not been made public.
What Carelogy does
Established in February 2021, Carelogy specializes in developing health technology for pets, specifically focusing on feline welfare. Its flagship product, ‘CatsMe,’ is an artificial intelligence application designed to identify signs of pain in cats by analyzing their facial expressions. The app processes images of a cat’s face to determine if the animal is experiencing discomfort.
Beyond simple detection, CatsMe offers personalized advice to users by analyzing daily pain detection results, recorded data, and user-inputted notes. The app also incorporates an AI insight feature, providing a summary of the cat’s condition over the preceding two weeks. This functionality aims to assist pet owners in various scenarios, such as during veterinary visits or when sharing information with others involved in the cat’s care. CatsMe is currently available on both iOS and Android platforms.
The application has seen rapid growth since its initial launch. An earlier version, known as ‘CPD (Cat Pain Detector),’ was released in May 2023. This was followed by a significant rebranding and relaunch as ‘CatsMe’ in January 2024. In just over a year since its initial service launch, the app has attracted more than 240,000 users across approximately 50 countries globally.
What the funding will do
While the specific intended use of the recently secured JPY 70.0 million has not been explicitly disclosed, Carelogy has outlined plans for future development and expansion. The company aims to accelerate its global presence, with a global release of the app planned for January of this year. Looking ahead, Carelogy intends to integrate features that allow for collaboration with veterinary hospitals and to forge business partnerships with other companies in the cat-related industry. These strategic moves are geared towards evolving CatsMe into a comprehensive support service for cat ownership.
Why it matters
The investment in Carelogy highlights a growing interest in leveraging artificial intelligence for pet health monitoring. As pet ownership continues to rise globally, so does the demand for innovative solutions that can enhance animal welfare and provide owners with better tools for care. Apps like CatsMe represent a significant step in this direction, offering non-invasive and accessible ways to detect health issues in pets, potentially leading to earlier intervention and improved outcomes. This seed round demonstrates investor confidence in the potential of AI-driven health apps within the burgeoning pet tech sector, particularly those addressing specific, often subtle, indicators of animal discomfort.